Sheila Ramos

Sheila Ramos serves as a key procurement lead within the National Cancer Institute (NCI), supporting the agency’s mission to accelerate cancer research through advanced scientific and technical solutions. She manages a diverse portfolio of acquisitions focused on research infrastructure, diagnostic innovation, and precision medicine technologies, ensuring alignment with NCI’s strategic priorities in genomic analysis and translational science. Her work centers on securing high-capability services that enable cutting-edge laboratory operations and data-driven research, often coordinating complex procurements across multiple technical domains to meet urgent scientific timelines. Ramos maintains a consistent working relationship with Roche Diagnostics Corporation, a primary vendor providing critical diagnostic platforms and laboratory services essential to NCI’s research ecosystem. Her contracting approach emphasizes collaboration with industry leaders capable of delivering scalable, compliant, and validated solutions, while also engaging a broader network of specialized service providers to meet evolving research needs. She fosters long-term vendor partnerships grounded in technical excellence, regulatory adherence, and agile delivery frameworks. Her procurement patterns reflect a balanced approach to socioeconomic goals, with 25% of awards designated for total small business set-asides under FAR 19.5, demonstrating a deliberate commitment to expanding opportunities for small and emerging firms. While the majority of acquisitions remain open to all competitors, she actively prioritizes small business participation in technical service categories where innovation and niche expertise are critical. Ramos’s primary focus areas include NAICS 541690 (scientific consulting), 541511 (custom computer programming), 541990 (other professional scientific services), and 541380 (testing laboratories). She routinely procures bioinformatics platforms, laboratory automation systems, molecular diagnostics, and data analysis services tailored to cancer genomics and precision oncology. Her expertise lies in bridging technical requirements with acquisition strategy to support mission-critical research initiatives across NCI’s nationwide network of laboratories and clinical partners.